[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337055-105":59,"doc-detail-337055-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","il-18r-supported-car-t-cells-targeting-oncofetal-tenascin-c-for-the-immunotherapy-of-pediatric-sarcoma-and-brain-tumors","IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors","","Oncofetal splice variants of extracellular matrix proteins provide target antigens for pediatric cancer immunotherapy, yet the feasibility of directing T cells with chimeric antigen receptors remains limited. This study quantified oncofetal tenascin C C-domain expression in pediatric brain and solid tumors using qRT-PCR and immunohistochemistry, then generated C.TNC-specific CAR T cells from human peripheral blood mononuclear cells for in vitro and in vivo evaluation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/il-18r-supported-car-t-cells-targeting-oncofetal-tenascin-c-for-the-immunotherapy-of-pediatric-sarcoma-and-brain-tumors/337055/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/il-18r-supported-car-t-cells-targeting-oncofetal-tenascin-c-for-the-immunotherapy-of-pediatric-sarcoma-and-brain-tumors/337055.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main target for CAR T cells in pediatric tumors?","Question",{"text":112,"@type":113},"The study targets the C domain of oncofetal tenascin C (C.TNC) using C.TNC-CAR T cells for immunotherapy of pediatric sarcomas and brain tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was C.TNC expression assessed in pediatric brain and solid tumors?",{"text":117,"@type":113},"C.TNC expression was measured using quantitative reverse transcription PCR and immunohistochemistry in pediatric brain and solid tumor samples.",{"name":119,"@type":110,"acceptedAnswer":120},"What strategy was used to improve the antitumor activity of C.TNC-CAR T cells?",{"text":121,"@type":113},"The researchers introduced a leucine zipper-based chimeric cytokine receptor that activates interleukin-18 signaling (Zip18R), creating C.TNC-CAR.Zip18R T cells to enhance cytokine secretion, expansion, and in vivo antitumor activity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337055,1790789287,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Open access Original research  \nIL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors  \nElizabeth Wickman  ,1,2 Shannon Lange,1 Jessica Wagner,1 Jorge Ibanez,1 Liqing Tian,1 Meifen Lu,3 Heather Sheppard,3 Jason Chiang,3 Selene C Koo,3 Peter Vogel,3 Deanna Langfitt,1 S Scott Perry,1 Raghuvaran Shanmugam,4 Matthew Bell,1 Timothy I Shaw,5 Giedre Krenciute  ,1 Jinghui Zhang,6 Stephen Gottschalk  1  \nTo cite: Wickman E, Lange S, Wagner J, et al. IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors. Journal for ImmunoTherapy of Cancer 2024;12:e009743 . doi:10.1136/jitc-2024-009743  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-009743](jitc-2024-009743)) .  \nAccepted 17 October 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Stephen Gottschalk;  \n[stephen.gottschalk@stjude.org](stephen.gottschalk@stjude.org)  \nABSTRACT  \nBackground Oncofetal splice variants of extracellular matrix (ECM) proteins present a unique group of target antigens for the immunotherapy of pediatric cancers. However, limited data is available if these splice variants can be targeted with T cells expressing chimeric antigen receptors (CARs) .  \nMethods To determine the expression of the oncofetal version of tenascin C (TNC) encoding the C domain (C.TNC) in pediatric brain and solid tumors, we used quantitative reverse transcription PCR and immunohistochemistry. Genetically modified T cells were generated from human peripheral blood mononuclear cells and evaluated in vitro and in vivo.  \nResults We demonstrate that C.TNC is expressed on a protein level in pediatric tumors, including diffuse intrinsic pontine glioma, osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma. We generate C.TNC-CAR T cells and establish that these recognize and kill C.TNC-positive tumor cells. However, their antitumor activity in vivo is limited. To improve the effector function of C.TNC-CAR T cells, we design a leucine zipper-based chimeric cytokine receptor that activates interleukin-18 signaling pathways (Zip18R) . Expression of Zip18R in C.TNC-CAR T cells improves their ability to secrete cytokines and expand in repeat stimulation assays. C.TNC-CAR.Zip18R T cells also have significantly greater antitumor activity in vivo compared with unmodified C.TNC-CAR T cells. Conclusions Our study identifies the C domain of the ECM protein TNC as a promising CAR T-cell therapy for pediatric solid tumors and brain tumors. While we focus here on pediatric cancer, our work has relevance to abroad range of adult cancers that express C.TNC.  \nINTRODUCTION  \nChimeric antigen receptor (CAR) T-cell therapy has shown promise for pediatric hematological malignancies; however, progress in the solid and brain tumor space has been limited.1–3 Although failure of CAR T cells in solid tumors is likely a multifactorial  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Oncofetal splice variants of extracellular matrix (ECM) proteins have so far been studied mainly in adult cancers, and the majority of ECM-targeted therapeutic approaches rely on antibody drug, cytokine, or radioisotope conjugates.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ We demonstrate here that the oncofetal version oftenascin C (TNC) encoding the C domain (C.TNC) is expressed on a protein level in both pediatric brain and solid tumors and can be targeted with C.TNCchimeric antigen receptor T cells.\u003Cbr>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY |\n\n⇒ Our study highlights that oncofetal splice variants of ECM proteins are viable targets for cellular immunotherapy.  \nissue, a critical first step to","cbCaiet9sc1Ewyyz","https://ap.wps.com/l/cbCaiet9sc1Ewyyz","pdf",5563519,15,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## CAR T-cell therapy background\n## Target antigen selection and oncofetal tenascin C\n## Cytokine engineering for CAR T cells","[{\"question\":\"What is the study’s main target for CAR T cells in pediatric tumors?\",\"answer\":\"The study targets the C domain of oncofetal tenascin C (C.TNC) using C.TNC-CAR T cells for immunotherapy of pediatric sarcomas and brain tumors.\"},{\"question\":\"How was C.TNC expression assessed in pediatric brain and solid tumors?\",\"answer\":\"C.TNC expression was measured using quantitative reverse transcription PCR and immunohistochemistry in pediatric brain and solid tumor samples.\"},{\"question\":\"What strategy was used to improve the antitumor activity of C.TNC-CAR T cells?\",\"answer\":\"The researchers introduced a leucine zipper-based chimeric cytokine receptor that activates interleukin-18 signaling (Zip18R), creating C.TNC-CAR.Zip18R T cells to enhance cytokine secretion, expansion, and in vivo antitumor activity.\"}]","IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors | PDF",1790017554,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b990b90def5d16d1fa6d41dec785d7ff.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53e14597089a2b5dffbda7b1b5bcb6c9.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36f8c6c51a18ba2fed2513549604a37c.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b125a389003d83a5e48411c45b489548.webp",980,1306]